These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist. Damiano BP; Mitchell JA; Giardino E; Corcoran T; Haertlein BJ; de Garavilla L; Kauffman JA; Hoekstra WJ; Maryanoff BE; Andrade-Gordon P Thromb Res; 2001 Oct; 104(2):113-26. PubMed ID: 11672755 [TBL] [Abstract][Full Text] [Related]
17. Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action. Olson RE; Sielecki TM; Wityak J; Pinto DJ; Batt DG; Frietze WE; Liu J; Tobin AE; Orwat MJ; Di Meo SV; Houghton GC; Lalka GK; Mousa SA; Racanelli AL; Hausner EA; Kapil RP; Rabel SR; Thoolen MJ; Reilly TM; Anderson PS; Wexler RR J Med Chem; 1999 Apr; 42(7):1178-92. PubMed ID: 10197962 [TBL] [Abstract][Full Text] [Related]
18. Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs. Hutchinson JH; Cook JJ; Brashear KM; Breslin MJ; Glass JD; Gould RJ; Halczenko W; Holahan MA; Lynch RJ; Sitko GR; Stranieri MT; Hartman GD J Med Chem; 1996 Nov; 39(23):4583-91. PubMed ID: 8917647 [TBL] [Abstract][Full Text] [Related]
19. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852 [TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Nannizzi-Alaimo L; Alves VL; Phillips DR Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]